MedTrace Logo

Acceptability of Artificial Intelligence in the Diagnosis of Prostate Cancer

NCT07074405 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-03-27

No results posted yet for this study

Summary

This study investigates the acceptability of artificial intelligence (AI) as a diagnostic support tool among patients with localized prostate cancer and healthcare providers, as well as their willingness to share health data for AI development.

Background AI tools in healthcare show promising potential, especially in improving diagnosis accuracy and personalizing treatment. However, successful implementation depends not only on technical performance but also on the acceptability of AI among its users-both patients and professionals. Prior research has shown varied acceptability depending on context, disease severity, task performed by AI, and user population.

Objectives Assess patients' acceptability of AI as a diagnostic support in prostate cancer.

Explore patients' willingness to share health data for developing clinical AI.

Assess healthcare providers' acceptability of AI in this diagnostic context.

Methodology Design: A cross-sectional, mixed-method, multinational study (Belgium, Italy, Spain).

Quantitative Phase: Online questionnaire, using adapted theoretical frameworks (Value Perception Model, NASSS-AI, TFA).

Qualitative Phase: Will follow based on quantitative findings.

Participants: Adults diagnosed with localized prostate cancer. Recruitment via hospitals, social media, and patient associations.

Data Collected: Personal and health information, attitudes toward AI, willingness to share data.

Ethics Approved by ethics committees in each participating country.

Informed consent obtained digitally before participation.

Data anonymized and GDPR-compliant.

Conditions

Interventions

OTHER

Questionnaire and Physical Exam

This is an online questionnaire that the patients fill in

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Liege

    lead OTHER

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-02
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07074405 on ClinicalTrials.gov